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Abstract
Cone dystrophy 3 (COD3) is a severe dominantly inherited retinal degeneration caused by missense mutations in GUCA1A,
the gene encoding Guanylate Cyclase Activating Protein 1 (GCAP1). The role of GCAP1 in controlling cyclic nucleotide levels
in photoreceptors has largely been elucidated using knock-out mice, but the disease pathology in these mice cannot be
extrapolated directly to COD3 as this involves altered, rather than loss of, GCAP1 function. Therefore, in order to evaluate
the pathology of this dominant disorder, we have introduced a point mutation into the murine Guca1a gene that causes an
E155G amino acid substitution; this is one of the disease-causing mutations found in COD3 patients. Disease progression in
this novel mouse model of cone dystrophy was determined by a variety of techniques including electroretinography (ERG),
retinal histology, immunohistochemistry and measurement of cGMP levels. It was established that although retinal
development was normal up to 3 months of age, there was a subsequent progressive decline in retinal function, with a far
greater alteration in cone than rod responses, associated with a corresponding loss of photoreceptors. In addition, we have
demonstrated that accumulation of cyclic GMP precedes the observed retinal degeneration and is likely to contribute to the
disease mechanism. Importantly, this knock-in mutant mouse has many features in common with the human disease,
thereby making it an excellent model to further probe disease pathogenesis and investigate therapeutic interventions.
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Introduction
Inherited cone dystrophies affect around 1/10,000 people [1].
Patients typically present with progressive loss of central vision and
reduced colour vision in the second to third decades of life [2].
Mutations in several genes are now known to cause inherited cone
dystrophies [2]. The first such mutation to be identified was in
GUCA1A encoding Guanylate Cyclase Activating Protein 1
(GCAP1), a component of the phototransduction cascade [3].
GCAP1 is expressed in both rod and cone photoreceptors, where
it plays a critical role in recovery following photon capture, by
stimulating retinal Guanylate Cyclase (retGC1) to produce cyclic
GMP (cGMP) in a Ca2+-dependent manner [4–6]. GCAP1 acts as
a Ca2+ sensor by binding Ca2+ ions to three of its four EF-hand
domains when the intracellular Ca2+ concentration rises to around
500 nM in the ‘dark state’; in its Ca2+-bound state GCAP1
represses retGC1 activity, ensuring that cGMP levels do not rise
above the 10–30 mM needed to keep the cGMP-gated (CNG)
cation channels open [6–8]. Following the light-activated hydro-
lysis of cGMP, the CNG cation channels close thereby reducing
influx of Ca2+. Since Ca2+ continues to be extruded, this results in
a reduction in intracellular Ca2+ concentration and the dissocia-
tion of Ca2+ ions from GCAP1, which in its unbound state permits
retGC-mediated cGMP production. This increase in cGMP
results in the opening of the CNG cation channels, allowing the
influx of Ca2+ ions and a restoration of the resting levels of cyclase
activity.
The first mutation in GUCA1A to be associated with dominant
cone dystrophy was an A-to-G missense mutation in codon 99 that
results in the replacement of tyrosine with cysteine (Y99C) in EF3
of the GCAP1 protein [3]. The binding of Ca2+ ions to GCAP1 is
thereby reduced, making the cyclase activity less responsive to
Ca2+ concentration and leading to constitutive activation of
retGC1 by the mutant GCAP1 [9]. Subsequently, several other
mutations in GUCA1A have been shown to alter amino acids
predicted to form or stabilise Ca2+-binding EF-hand motifs in
GCAP1, thereby causing a similar loss of Ca2+-sensitivity and
constitutive activation of retGC-mediated cGMP production
(reviewed in [10]). All have been associated with dominant cone
dystrophy [11–15].
Although these mutations in GUCA1A affect the function of
GCAP1 protein by a common mechanism, there is considerable
inter- and intra-familial heterogeneity in the associated clinical
phenotypes. In the majority of cases, patients carrying mutations
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in GUCA1A have little or no reduction in peripheral visual field
and night vision, but experience marked photophobia and
significantly impaired colour vision and visual acuity – consistent
with the sparing of rod function and the classification of disease as
a cone dystrophy. However, a number of patients with mutations
in GUCA1A have reduced rod as well as cone function; whilst the
disorder in most patients with Y99C and L151F mutations is
reported as cone dystrophy with normal rod-mediated vision,
some affected individuals from the same families have altered rod
function and present as a cone-rod dystrophy [14,16]. It is unclear
why mutations that result in similar biochemical defects have such
varied clinical sequelae; specifically, it is not known whether rod
involvement in some patients is a direct result of the mutations in
GUCA1A, or due to the presence of modifier loci.
Animal models of disease have provided some insight into the
role that mutant GCAP1 may play in retinal pathology. The
murine Guca1a and Guca1b genes, encoding GCAP1 and 2
respectively, are in a tail-to-tail array on chromosome 17, and
this provided a simple strategy via a double knock-out mutation, to
study the impact of a complete loss of GCAP function in the
mouse [17]. Although the human disease associated with
mutations in GUCA1A is attributed to gain-of-function mutations
and the knock-out mice have no discernible retinal degeneration,
this study has advanced our understanding of the regulation of
guanylate cyclase activity by GCAP proteins.
A transgenic mouse line with a mutant Y99C bovine GCAP1
cDNA transgene driven by a rhodopsin promoter has been shown to
exhibit a severe early-onset retinal disease with dysregulation of Ca2+-
dependent retGC1 activation [18]. Disease in this transgenic mouse
line differs therefore from the human disorder since mutant GCAP1
will be present only in rod photoreceptors, whereas the human
disease was originally described as a cone dystrophy. Perhaps not
surprisingly therefore, there are significant differences in the pattern
and rate of loss of rods and cones in the transgenic mouse [18]
compared to the human disease, indicating that the disease pathology
generated by the mutant transgene is significantly different from the
human disorder. The transgenic mouse is not therefore a suitable
animal model for assessing disease treatment of the human disease.
We have therefore chosen to generate a more accurate model of
the human disease via a gene targeting approach, by introducing a
point mutation into the endogenous promoter. The advantage of
such an approach is that the control of gene expression remains
under the endogenous promoter, allowing the consequences of the
mutation to be studied without the significant complications of over-
expression associated with multiple copies of a transgene and
heterologous regulation. Such targeted introductions of mutations to
generate ‘‘knock-in’’ mutant mice, have recently been used to create
models of ocular disease that closely mimic their human counterparts
[19–21]. In this study we have generated a knock-in model of the
disease-causing E155G amino acid substitution in EF4 of GCAP1
[22]. Our model demonstrates that mutant GCAP1, when under
normal expression control, causes both rod and cone photoreceptors
to lose function and degenerate, with cone cells being more severely
affected, in keeping with the human disease phenotype. This will
enable a greater understanding of the progression andmechanisms of
disease in COD3 patients and provide a more informative and
reliable means of investigating treatment strategies.
Results
Gene targeting approach yields ‘knock-in’ mice with
mutant Guca1a
A plasmid containing the full murine Guca1a locus, with the
introduction of an A-to-G substitution at base-pair 19 of exon 4
and a neomycin-resistance gene in intron 3, was generated as
shown in Figure 1 and used for the targeting of the Guca1a gene.
The resulting Guca1aCOD3 mice were genotyped using primers that
flanked a residual intronic loxP sequence to identify gene-targeted
allele; the PCR products from homozygous and heterozygous mice
(shown in Figure 1b) were sequenced to determine whether the
loxP sequence segregated with the A-to-G transversion. As shown
in Figure 1c, the point mutation was present in all targeted
alleles. The targeted or mutant allele is referred to here as
Guca1aCOD3. From the F1 mice, heterozygous Guca1a+/COD3 and
homozygous Guca1aCOD3/COD3 mutant mice were generated; in
this study we present data from both mutant genotypes as the
former represents a close correlate to patients with COD3, whilst
the latter may provide further insights into the role that mutant
GCAP1 plays in causing cone and cone-rod dystrophy.
GCAP1 levels and effect on other photoreceptor proteins
in pre-symptomatic mutant mice
The gene targeting approach enables us to study the
consequences of a clinically relevant mutation in an endogenous
gene, leaving the rest of the gene intact and under normal
expression control. To ensure the introduction of the E155G
mutation in GCAP1 did not alter the expression level of GCAP1
protein prior to the onset of retinal dysfunction, a time point of 6
weeks of age was selected when retinal structure and function
appeared to be normal (see below). The amount of GCAP1
protein present was assayed by Western blotting; as shown in
Figure 2a, there is no substantive change in retinal GCAP1
protein level in either heterozygous or homozygous mutant mice,
compared with wild-type mice of similar age. This analysis was
then extended to a panel of photoreceptor markers: rod-specific
phosphodiesterase (PDE6b) cone-specific L/M opsin, cone-specific
transducin (GNAT2), and retGC. Western blot analysis again
showed no substantive changes in the protein levels of any of these
photoreceptor-specific proteins in heterozygous or homozygous
mice compared with wild-type littermates (Figure 2b). The levels
of these phototransduction cascade proteins are unaffected
therefore at 6 weeks of age by the production of mutant GCAP1,
indicating that photoreceptors develop normally in mutant mice
prior to the onset of the pathological changes, described below.
Elevated intracellular cGMP levels in mutant mice
Since mutant GCAP1 protein has been shown in vitro to result in
loss of Ca2+-sensitivity and the constitutive activation of retGC1
[22], mutant mice would be expected to show elevated levels of
cGMP production. Therefore, cGMP levels were measured from
the retinae of 6 week-old mutant mice and wild-type littermates.
As shown in Table 1, cGMP levels in homozygous mice were
significantly elevated compared with wild-type littermates, with
heterozygous mice also showing elevated levels that fall just short
of statistical significance. This indicates that prior to the
development of an overt phenotype as measured by retinal
function, cGMP levels are already elevated in mutant mice.
Photoreceptor function in mutant mice
ERGs were recorded from mutant mice and wild-type
littermates to determine the effects of the E115G mutation in
GCAP1 on retinal function. Although retinal function in young
mutant mice appeared to be normal, from three months of age
cone function in heterozygous Guca1a+/COD3 mice was significant-
ly reduced. At five months of age, there was a marked reduction in
the cone-mediated light-adapted (photopic) ERG in mutant mice
(Figures 3a, c), with a b-wave amplitude of 119.7620.5 mV in
Dominant Cone-Rod Dystrophy
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Guca1a+/COD3 mice compared with 172.2632.0 mV in wild-type
littermates (p = 0.003). The 10 Hz and 15 Hz cone flicker ERG
responses were severely depressed in Guca1a+/COD3 mice, in
keeping with profound loss of cone function (Figure 4a). This
reduction in cone responses progressed with age, with 12 month-
old Guca1a+/COD3 mice retaining 42% of the photopic ERG b-
wave amplitude of their wild-type littermates (Figure 3a, c).
Homozygous Guca1aCOD3/COD3 mice also showed a significant
reduction in cone function, with light-adapted b-waves down to
92.4614.7 mV and flicker responses absent at five months of age
(Figure 3a). As a proportion of age-matched wild-type litter-
mates, 12 month-old Guca1aCOD3/COD3 mice retain just 17% cone
function (Figure 3b, d).
There was also a reduction in the rod-mediated dark-adapted
(scotopic) ERG that was apparent from three months of age. At
five months of age (Figure 4a), dark-adapted b-wave amplitudes
from Guca1a+/COD3 mice (234.6657.3 mV) were significantly
reduced compared with those from wild-type littermates
(388.2680.1 mV, p,0.001). The loss of rod function in mutant
mice continued over time; however, there was also a concomitant
reduction in rod function in wild-type littermates such that
Guca1a+/COD3 mice retained 74% of wild-type scotopic b-wave
amplitudes (Figure 4c, d). It is noteworthy therefore that overall,
cone photoreceptor dysfunction was more severe than rod
dysfunction in Guca1a+/COD3 mice. Homozygous Guca1aCOD3/COD3
mice suffered a greater loss in rod function (average scotopic b-wave
amplitude was 179.763.6 mV at five months of age); at 12 months
of age homozygousGuca1aCOD3/COD3 mice retained only 44% of the
b-wave amplitude of wild-type littermates.
Impaired rod recovery kinetics in mutant mice as
measured by paired-flash ERG
Since GCAP1 has a role in recovery following activation of the
phototransduction cascade, we used a paired-flash ERG method
to determine whether the rate of recovery from a bright flash was
disturbed in mutant mice. Paired flash responses have been used
successfully to determine the rate of recovery of photoreceptor
currents in vivo, [23–30], and are known to be reduced in patients
with COD3 [15]. Paired-flash ERG responses were therefore used
to monitor the kinetics of recovery in dark-adapted mutant mice
and wild-type littermates. Since ,5% of the saturated a-wave is
due to cones [31–33], the a-wave in these responses can be
attributed almost entirely to rod function. Dark-adapted mice were
exposed to a bright conditioning flash, followed by a second probe
flash at varying intervals. The a-wave amplitudes elicited by the
latter were then plotted as a proportion of the former against time
(Figure 5). In wild-type mice, the a-wave from the probe flash
recovers fully within two seconds, whereas in both Guca1a+/COD3
and Guca1aCOD3/COD3 mice, recovery was delayed, with only
around 65% recovery of the a-wave within 2 seconds of the
conditioning flash, with the time to half-recovery (where the probe
flash gives rise to an a-wave amplitude half that of the first)
Figure 1. Generation of Guca1aCOD3 ‘knock-in’ mice with E155G mutation in GCAP1. (a) A vector targeting the endogenous Guca1a locus
was constructed to include an A-to-G transversion at nucleotide position 19 in exon 4 of Guca1a (red circle), as well as a loxP-flanked (blue arrow
heads) neomycin resistance gene within intron 3. Following Cre-mediated excision of the Neo selectable marker, the resulting locus contained the A-
to-G change in exon 4 plus a residual 34 bp loxP sequence in intron 3. This was used to distinguish between mutant and native alleles by PCR – the
position of the primers used is indicated by the small blue arrows on the Cre-deleted Guca1a locus. (b) PCR amplicons from wild-type, Guca1a+/COD3
and Guca1aCOD3/COD3 mice (lanes 3, 4 and 5 respectively), with 1 kb DNA ladder (lane 1) and no-DNA control (lane 2). The wild type allele generates a
band at 734 bp whereas the mutant allele generates a 768 bp band which includes the residual intronic loxP sequence. Wild-type mice have
therefore a single band at 734 bp, homozygous Guca1aCOD3/COD3 mice have a single band at 768 bp, and heterozygous Guca1a+/COD3 mice have both
bands. (c) Sequence of wild type and targeted Guca1a allele showing A-to-G transversion at nucleotide position 19 of exon 4.
doi:10.1371/journal.pone.0018089.g001
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extended from 1000 ms in wild type to 1600 ms in heterozygous
and homozygous mutant mice. These observations clearly
demonstrate that, in vivo, there is impaired recovery of rod
photoreceptors from a bleaching flash in mutant mice.
Cone and rod opsin expression and cone loss
To further assess the effect of mutant GCAP1 on other
components of the phototransduction cascade, the expression of
L/M- and S-opsin in cones and rod opsin (rhodopsin) in rods was
examined immunohistochemically using specific antibodies on
frozen retinal tissue. At five months of age, there were fewer cone
photoreceptors expressing cone opsins in Guca1a+/COD3 and
Guca1aCOD3/COD3 mice (Figure 6a). In contrast, the expression
of rod opsin in rod outer segments shows less of a decline
(Figure 6b). Flat mounts were then used to quantify the number
of opsin-expressing cones remaining in mutant retinae at five and
12 months of age. At five months of age there was a significant
loss of cones; heterozygous Guca1a+/COD3 and homozygous
Guca1aCOD3/COD3 mice retained 52% and 44% of opsin-expressing
cells compared with wild-type littermates (Figure 7a and c). In
keeping with these findings, there was also a loss of PNA-positive
cells; at five months of age Guca1a+/COD3 mice retained 72%
and Guca1aCOD3/COD3 mice retained 62% PNA-positive cells
when compared with wild-type littermates. The loss of cone
cells was progressive, and at twelve months of age heteroz-
ygous Guca1a+/COD3 mice retained 38% and homozygous
Guca1aCOD3/COD3 mice retained only 16% of cone opsin-positive
cells compared with age-matched wild-type littermates (Figure 7a
and c). The loss of PNA-positive cells also continued over time,
such that at twelve months of age Guca1a+/COD3 mice retained
61% and Guca1aCOD3/COD3 mice retained 36% as compared with
wild-type littermates.
Photoreceptor loss in mutant mice
Since GCAP1 is expressed in both rod and cone photoreceptors,
with evidence of greater expression in cones than rods [34], and
mutant mice show a significant reduction in rod function, we
performed histological analysis of the retina at various ages to
ascertain whether the loss of retinal function with age was associated
with disturbed retinal architecture. The retina appeared to develop
normally, with no evident loss of photoreceptors at two months of
age, in both Guca1a+/COD3 and Guca1aCOD3/COD3 mice (data not
shown). However, at five months of age there was a marked
reduction in the thickness of the outer nuclear layer (ONL) in both
heterozygous and homozygous mutant mice, indicating a loss of
photoreceptor nuclei. As evident in resin-embedded semi-thin
sections, the remaining photoreceptor cells appear to have
shortened and/or dysmorphic outer segments, both of which are
common features of retinal degeneration [35–39] (Figure 8a, b
and c). Quantitative analysis performed on paraffin-embedded
sections showed that at five months of age, the loss of photoreceptors
in mutant mice was significant, with Guca1a+/COD3 mice retaining
69% of cells in the ONL compared with wild-type littermates
(Figure 8d). However, the rate of loss of photoreceptor nuclei
appears to decline with age, since by 12 months of age
Guca1a+/COD3 mice still retained 67% of cells in the ONL compared
with wild-type littermates (Figure 8e). Guca1aCOD3/COD3 mice also
showed a thinning of the ONL, retaining 54% of cells in the ONL
compared to wild-type littermates at five months of age (Figure 8d)
and 51% at 12 months (Figure 8e).
Discussion
A key step in phototransduction in vertebrates is the closure of
cGMP-gated cation channels and the continued active efflux of
Ca2+ as a result of a cascade initiated by photon capture by the
visual pigment, with subsequent breakdown of cGMP by the
activation of phosphodiesterase activity. This process is reversed
by the synthesis of cGMP at low intracellular Ca2+ concentrations
Figure 2. Photoreceptor-specific protein expression levels in
young Guca1aCOD3 ‘knock-in’ mice. Western blots from retinal
homogenates taken from six week-old wild-type (WT), heterozygous
(Het) and homozygous (Hom) mutant mice. Equally loaded protein
extracts were blotted with anti-b-actin as a loading control. (a) a-GCAP1
antibody DSC-1 with the retinae from three eyes per genotype. (b)
PDE6b (rod-specific), L/M opsin, GaT2 (GNAT2 - cone-specific a-
transducin) and retGC (rod and cone) antibodies, with the retinae from
a single eye per genotype. In all cases, there are no discernible
differences in staining between genotypes.
doi:10.1371/journal.pone.0018089.g002
Table 1. cGMP levels in retinae of Guca1aCOD3 ‘knock-in’
mice.
Genotype cGMP P values
fmol/mg protein (mutant v wild type)
Wild type 77.069.3
Guca1a+/COD3 100.6623.1 0.09
Guca1aCOD3/COD3 124.6616.0 ,0.01
cGMP levels were measured in six week-old mice, before the onset of
degeneration as evidenced by retinal structure and function. Levels of cGMP
were corrected for total protein content of each sample.
doi:10.1371/journal.pone.0018089.t001
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via the activation of guanylate cyclase by GCAPs. In the mouse
model characterised in this study, the regulation of this latter
process has been altered by the introduction of a single nucleotide
missense mutation in the endogenous Guca1a gene using gene
targeting. The mutated gene encodes a E155G substitution in EF4
of the GCAP1 protein; Ca2+ binding to the mutant GCAP1 is
reduced to only two hands (EF2 and EF3) and thereby reduces the
feedback loop [17,40] whereby cyclase activity is reduced as Ca2+
concentrations in photoreceptors are brought back to dark-state
levels. Consistent with this, we have shown that retinal levels of
cGMP in mutant mice are elevated prior to the development of
any overt pathology.
The retinal disease seen in human patients with dominant
mutations in GUCA1A was originally described as an isolated cone
dystrophy, but recent evidence suggests that secondary loss of rod
function may occur in some patients, particularly at later stages of
disease [16]. The mouse mutant confirms the involvement of cones
and rods, with both showing a progressive decline in function from
3 months of age as determined by ERG responses; although, in
keeping with the human disorder, the decline in cone-mediated
responses was greater than the decline in rod-mediated responses
once the age-related loss of rod function is taken into account.
Prior to the 3 month time point, ERGs recorded in wild type and
mutant mice were indistinguishable, as was retinal morphology
and the expression of cone and rod photoreceptor markers,
indicating that retinal function and structure was initially normal.
As the disease developed in Guca1aCOD3 mutant mice, there was a
progressive reduction in the thickness of the photoreceptor cell
layer, a progressive depression in ERG amplitude and a reduction
in the number of cones. Although a previous study describing a
transgenic mouse carrying a Y99C mutant bovine GCAP1
transgene also showed significant rod degeneration, this can be
attributed to the fact that the transgene was expressed predom-
inantly – if not exclusively – in rods [16]. In direct contrast, the
phenotype in the model characterised here, with a greater impact
on cones than on rods, is likely to be a direct consequence of the
point mutation in GCAP1.
A role for GCAP1 in phototransduction in both rods and cones
is indicated by various studies of GCAP knock-out mice. Mice with
a double GCAP1 and GCAP2 knock-out show an altered response
of rods to saturating flashes of light which is not rescued by the
production of GCAP2 from a transgene [17], whereas the degree
of recovery post-flash in rods [31] and cones [41] has been shown
to correlate with the level of GCAP1 expression in these mice
Figure 3. Electroretinography of Guca1aCOD3 ‘knock-in’ mice. (a) Representative ERG traces recorded at five months of age. Light-adapted,
cone-mediated ERG (upper trace, right eye, lower trace, left eye) is reduced in Guca1a+/COD3 and Guca1aCOD3/COD3 mice compared to wild-type
littermates, as is the cone-mediated flicker response to 10- and 15-Hz stimuli (* and # respectively). (b) Representative ERG traces recorded at 12
months of age. There is a greater reduction in cone function in mutant mice, with light-adapted flash responses further attenuated and flicker
responses almost extinguished. (c) Averaged photopic, cone-mediated b-wave amplitudes from wild-type, Guca1a+/COD3 and Guca1aCOD3/COD3 mice
recorded over a twelve month period from birth. There is a progressive loss of cone function over time in both heterozygous and homozygous
mutant mice compared to wild-type littermates (n= 8 per genotype). (d) ERG b-wave amplitudes from Guca1a+/COD3 and Guca1aCOD3/COD3 mice
plotted as a percentage of wild-type amplitudes over a twelve month period from birth.
doi:10.1371/journal.pone.0018089.g003
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when expressing a GCAP1 transgene. GCAP2 is also capable of
regulating cGMP production by retGC1 in a Ca2+-dependent
manner [17]. Since GCAP2 is predominantly expressed in rods
[4,42,43], the loss of Ca2+-sensitivity due to the E155G mutation
in GCAP1 may be compensated for by GCAP2 to a greater extent
in rods than in cones, and may thereby account for the increased
loss of cones compared with rods in both the animal model and
human disease. In contrast, as shown by the GCAP1 and GCAP2
double knock-out, the loss of all GCAP function does not result in
retinal degeneration [17].
The causal relationship between photoreceptor degeneration
and mutant GCAP1 has yet to be fully established. Previous work
with transgenic mice expressing mutant GCAP1 protein has
shown elevated levels of intracellular Ca2+ [18]. This is also the
predicted consequence of the elevated cGMP levels seen in the
Guca1aCOD3 mutant mice. Elevated levels of Ca2+ have been
shown to activate apoptotic pathways in rod photoreceptors [44]
and may therefore be the major factor in the retinal degeneration
in these mice, and in the human disease. The same may be the
case in rd1 mutant mice which either lack [45] or have severely
reduced levels [46] of the cGMP-phosphodiesterase. It has also
been reported in one study that D-cis-diltiazem, a calcium-channel
blocker, rescues photoreceptors and preserves visual function in
these mice [47] although other studies have failed to confirm these
findings [48,49].
Both heterozygous and homozygous Guca1aCOD3 mutant mice
showed a significant delay in the recovery of the rod ERG a-wave
after a bright conditioning flash. In vitro, mutant E155G GCAP1
results in a reduced sensitivity of cyclase activity to Ca2+ inhibition
[22], and the elevated levels of cGMP seen in the retinae of the
Figure 4. Reduced rod function in Guca1aCOD3 ‘knock-in’ mice. (a) Representative ERG traces taken from dark-adapted 5 month-old wild-type,
Guca1a+/COD3 and Guca1aCOD3/COD3 mice, showing a reduction in a- and b-wave amplitude in mutant mice in the rod-dominated ERG in response to a
series of increasing stimulus intensities. (b) Representative ERG traces taken from dark-adapted 12 month-old wild-type, Guca1a+/COD3 and
Guca1aCOD3/COD3 mice, showing that rod function is relatively spared when compared with cone function. (c) Averaged scotopic, rod-dominated b-
wave amplitudes from wild-type, Guca1a+/COD3 and Guca1aCOD3/COD3 mice recorded over a twelve month period from birth. Mean values were
calculated from b-wave amplitudes from 100 mcds/m2 flash intensity, which corresponds to a rod-only response. Note the age-related decline in
wild-type mice. (d) Rod b-wave amplitudes in Guca1a+/COD3 and Guca1aCOD3/COD3 mice plotted as a percentage of wild-type amplitudes over a twelve
month period from birth.
doi:10.1371/journal.pone.0018089.g004
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Guca1aCOD3 mutant mice indicate that the mutant GCAP1 is
having a similar effect in vivo, so the delay in recovery is
presumably a consequence of these elevated levels of cGMP. A
delay in recovery of the rod a-wave is also seen in mice lacking
both GCAP1 and GCAP2. This delay was reversed by the
expression of GCAP1 via a transgene in a dose-dependent manner
[31], and the same was found for the delay in the cone response
[41]. Therefore, in both the GCAP1 knock-out and the E155G
GCAP1 knock-in mice, cyclase activity remains elevated in the
absence of GCAP-mediated Ca2+ regulation. Importantly, this
delay in rod recovery is also a salient feature of the human disease,
as described in the case of an N104K mutation in GCAP1 [15].
Since the phenotype presented here can be attributed to a single
point mutation introduced into the native gene and independent
therefore of positional effects and copy number variations resulting
from transgenic lines generated by pronuclear injections of DNA
constructs, we believe that the Guca1aCOD3 mutant mouse line
represents a more accurate model of human cone dystrophy 3, and
displays all the characteristic phenotypic hallmarks of the human
disorder. In addition, the mouse model has demonstrated that
cGMP levels are elevated prior to any depression in retinal
function, indicating that this may be the trigger for the subsequent
degenerative changes, and that there is a significant loss of
photoreceptors as the disease progresses, although this is less
evident for rods than for cones. The knock-in mouse model is
likely to prove therefore to be a very useful platform for the testing
of potential treatments such as pharmacological intervention and
viral vector-mediated genetic therapies.
Materials and Methods
Ethics statement
All animal studies were carried out under the Animals (Scientific
Procedures) Act 1986 under a project license PPL70/6115 issued
by the UK Government Home Office and conducted in
accordance with protocols approved by the Animal Ethics
Committee of the UCL Institute of Ophthalmology. All efforts
were made to minimize the number and suffering of animals used
in these experiments.
Generation of Guca1aCOD3 ‘knock-in’ mice
A plasmid construct targeting the endogenous mouse Guca1a
locus and including an A-to-G transversion at codon 155 was
transfected into 129 Sv mouse embryonic stem cells and resultant
neomycin-resistant clones were injected into blastocysts for the
production of chimeric mice. The neomycin cassette was flanked
by loxP sequences to allow for its subsequent excision by crossing
chimeric mice with mice expressing the Cre recombinase under the
control of a ubiquitous CMV promoter. The screening of the
resultant mice by PCR-amplification and sequencing of the region
confirmed the presence of the point mutation and the successful
removal of the neomycin cassette in the Cre-deleted mutant
GCAP1 allele. These F1 mice were genotyped using PCR primers
that flanked the targeted exon and the residual loxP sequence; the
targeted allele, which included the single surviving intronic loxP
sequence, gave a larger amplification product than the wild-type
allele (Figure 1). The resultant PCR products were directly
sequenced to verify that the A-to-G transversion segregated with
the targeted allele.
Western blotting
Six week-old Guca1aCOD3 mice and wild-type litter-mates
were sacrificed by cervical dislocation and the eyes were
removed. Retinae were dissected away from lens and RPE/
choroid, and for analysis of cytoplasmic proteins (i.e. GCAP1, b-
actin, PDE6b) were placed in RIPA buffer with added protease
inhibitor cocktail (Sigma Aldrich, Gillingham, UK). Cell
membranes were disrupted using a sonicator with a micro-tip
(Soniprep 150, MSE London UK). Lysates were archived at
280uC. For analysis of membrane-bound proteins (retGC,
GNAT2, cone opsins) membrane fractions were prepared by
homogenising tissue in low salt homogenization buffer (10 mM
MOPS pH 7.3, 5 mM mercaptoethanol, 20 mg/ml leupeptin,
1 mM PMSF) and the cells left to swell on ice for 10 min. The
cells were lysed by five passages through a 0.5 mm gauge
syringe needle. The salt content of the homogenate was then
raised to 0.25 M with 5 M NaCl and the homogenate was spun
at 4uC for 5 min at 900 g to remove large debris. Cell
membranes were pelleted by further centrifugation of the
supernatant at 14 926 g in a pre-cooled 4uC centrifuge for
30 min. Membrane pellets were resuspended in 150 ml of low
salt homogenization buffer. Equal amounts of protein, deter-
mined by a Lowry-based colorimetric protein assay performed
in triplicate (DC protein assay kit, Bio-Rad, Hemel Hempstead
UK) compared to a bovine serum albumin standard curve, were
run on a 9% (w/v) reducing SDS polyacrylamide electropho-
resis gel. After semi-dry transfer to PVDF membrane (Millipore
Watford UK) and blocking in 5% (w/v) non fat milk, 1% (w/v)
bovine serum albumin in PBS-T (phosphate buffered saline with
0.005% Tween-20), membranes were incubated with primary
antibodies. After washing in PBS-T, secondary antibody was
incubated at a concentration of 1:5000–1:10 000 for 1 hour at
room temperature (Pierce Immunopure goat anti-rabbit and
anti-mouse IgG (H+L) HRP conjugated, Perbio Science UK
Ltd., Northumberland UK). Chemiluminescence detection was
performed using a Fujifilm LAS-1000 Luminescence Image
Analyser after incubation with enhanced luminescence reagent
(ECL plus GE Healthcare UK Ltd. Amersham, UK).
Figure 5. Impaired recovery from bright flash of Guca1aCOD3
‘knock-in’ mice. The a-wave amplitude from a bright test flash,
presented at varying times after a conditioning flash, is plotted as a
proportion of the amplitude elicited by the conditioning flash. A value
of 0 indicates the amplitude from the second flash is the same as that
from the first; full recovery from a bright conditioning flash occurs
within two seconds in wild-type mice, and the second flash elicits an
amplitude half that of the first when the inter-stimulus interval is
approximately 1000 ms. This recovery time is extended to 1600 ms in
both heterozygous and homozygous knock-in mice, whilst the
amplitude from the second flash fails to reach that elicited by the
first flash during the time period of recording.
doi:10.1371/journal.pone.0018089.g005
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Measurement of intracellular cGMP levels
Mice were sacrificed in the dark under infra-red illumination
and retinae were dissected away from lens and RPE/choroid.
Manufacturer’s instructions for a cGMP competition ELISA
were followed to assay cGMP levels (cGMP BIOTRAK assay,
GE Healthcare UK Ltd. Amersham, UK). Briefly, cGMP was
extracted from the retina by homogenisation in 200 mL ice-cold
6% (w/v) tricholoroacetate, followed by centrifugation for
30 minutes at 2,000 g. The cell pellet obtained from this cGMP
isolation step was homogenised in RIPA buffer with added
protease inhibitor cocktail (Sigma Aldrich, Gillingham, UK),
and the amount of total protein in the sample quantified using a
Lowry-based colorimetric protein assay performed in triplicate
(DC protein assay kit, Bio-Rad, Hemel Hempstead UK)
compared to a bovine serum albumin standard curve. The
total protein content of each sample was used to correct the final
cGMP value obtained per mg of protein. The supernatant
containing cGMP was then washed four times with water-
saturated diethyl ether (Sigma Aldrich Ltd., Gillingham, UK),
with the aqueous phase recovered after each wash. After final
wash, the sample was placed in a vacuum concentrator to allow
evaporation of solvent and recovery of cGMP pellet which was
resuspended in 200 mL 16 assay buffer. Samples were then
applied in triplicate to a 96-well plate that was pre-coated with
anti-cGMP antibody, together with a standard curve of cGMP
at between 50 and 128,000 fmol. 100 mL of a separate anti-
cGMP antibody was then applied and incubated at 4uC
overnight, followed by 50 mL horseradish peroxidase-conjugat-
ed cGMP; after incubation at 4uC for four hours, the plate was
washed and TMB substrate applied to all wells. The coloured
product from the hydrolysis of this substrate was then quantified
using an automated plate reader at 630 nm, with cGMP in the
retinal samples competing out the cGMP in the assay kit,
thereby resulting in a lower optical density reading.
Figure 6. Mutant GCAP1 leads to progressive loss of cone photoreceptors. (a) Representative retinal flat mounts taken from 5 month-old
mice stained with PNA and anti-cone opsin antibody. There are fewer PNA-positive cone cells present in mutant compared to wild-type retinae, as
well as a fewer opsin-expressing cells in mutant versus wild-type retinae. Quantitative analysis shows that there are significantly fewer cone opsin-
expressing cells in mutant retinae than PNA-positive cells, although the labelling of both markers is significantly reduced in Guca1a+/COD3 and
Guca1aCOD3/COD3 mice as compared to wild-type littermates. (b) Representative retinal flatmounts taken from 12 month-old mice confirms
progression of cone degeneration; in mutant mice, there are fewer opsin-positive cells at 12 months compared to wild-type littermates.
doi:10.1371/journal.pone.0018089.g006
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ERG recordings
All animals were dark-adapted overnight (16 h), anaesthetized
and prepared for ERG recording as previously described [50].
Mice were then placed on a heated platform and ERGs recorded
using commercially available equipment (Espion E2; Diagnosys
LLC, Massachusetts USA) after corneal contact electrodes and
midline subdermal reference and ground electrodes were placed.
Bandpass filter cut-off frequencies were 1 and 300 Hz. Photopic
single-flash recordings were obtained at light intensities increasing
from 0.1 to 10000 mcds/m2 presented in a ganzfeld dome. Ten
responses per intensity level were averaged with an interstimulus
interval of 10 s (0.1, 1, 10 and 100 mcds/m2) or five responses per
intensity with a 60 s interval (3000, 5000 and 10000 mcds/m2).
Light-adapted, cone flicker responses were elicited in the presence
of a 41 cd/m2 rod-desensitizing white background with the flashes
of 10000 mcds/m2 presented at frequencies of 10 and 15 Hz.
Dark-adapted, rod dominated responses were elicited in the dark
using white light of intensities ranging from 0.001 to 3000 mcds/
Figure 7. Photopigment expression in ‘Guca1aCOD3 ‘knock-in’ mice. Representative cryosections from five month-old mice stained with DAPI
and (a) a combined anti-L/M- and S-cone opsin antibody (red) and PNA (green), and (b) an anti-rhodopsin (rod opsin) antibody (red). For both, upper
panels show fluorescent light micrographs, and lower panels show single slices from confocal microscopy. The expression of both cone and rod opsin
appears similar in both Guca1a+/COD3 and Guca1aCOD3/COD3 mice compared with wild-type littermates, although the rod opsin staining indicates a
shortening of rod outer segments. PNA staining (green) in (a) indicates a reduced number of cones in the mutant retinae which is more pronounced
in homozygous than in heterozygous mutant mice. INL inner nuclear layer, ONL outer nuclear layer, IS/OS inner segment/outer segment.
doi:10.1371/journal.pone.0018089.g007
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m2, with 10 responses per intensity and an interstimulus interval of
5 s (0.1, 1, 10 and 100 mcds/m2) or five responses per intensity
with a 60 s interval (1000 and 3000 mcds/m2).
Paired-flash ERGs were recorded by saturating the rods with a
25000 mcds/m2 flash at time T0, followed t-milliseconds later by a
test flash of equal intensity. The ratio between the a-wave elicited
by the test flash (A) and that from the probe flash (Amo) was then
calculated, and the Log10 of this value was plotted as a function of
time t as a measure of recovery which approached one as time t
was increased and the response to the test flash approached that to
the probe flash.
Immunohistochemistry
Animals were terminally anaesthetised and eyes were fixed by
intracardiac perfusion with 1% paraformaldehyde in PBS pH 7.4
and post fixed in 1–4% paraformaldehyde at room temperature.
Retinal cryosections were incubated for 1 h at room temperature
in PBS with 1% bovine serum albumin (BSA, Sigma Aldrich Ltd.
Gillingham, UK) and 5% normal goat serum (Abd serotec,
Kidlington UK). For retinal flatmounts, 0.05% (v/v) Triton X-100
(Sigma Aldrich Ltd., Gillingham UK) was added to the blocking
solution. For retinal cryosection analysis (n = 4 eyes for each
genotype), 12 mm retinal sections were incubated with 4D2 anti-
rhodopsin antibody or anti-cone opsin antibodies at 1:250 dilution
in blocking solution for 1 hour at room temperature. For retinal
flatmount examination (n= 4 eyes for each genotype), eyecups
with the cornea and lens removed were incubated with anti-cone
opsin antibodies at a dilution of 1:100 in blocking solution for
4 hours at 37uC. Counterstaining with biotinylated PNA (Sigma
Aldrich, Gillingham, UK) was performed at a concentration of
Figure 8. E155G mutation in GCAP1 causes photoreceptor degeneration. Photomicrographs of resin-embedded sections from (a) wild-type
(b) Guca1a+/COD3, and (c) Guca1aCOD3/COD3 mice at five months of age. There is a marked thinning of the outer nuclear layer (ONL) in mutant eyes as
shown by the loss of photoreceptor nuclei. There is also an apparent shortening of outer segment length, particularly in the Guca1aCOD3/COD3
homozygous mice. Photoreceptor loss in Guca1a+/COD3 and Guca1aCOD3/COD3 mice was quantified by counting photoreceptor nuclei in
photomicrographs of sections from paraffin-embedded eyes taken at fixed positions around the optic nerve. At five months of age (d), there is 30%
loss in Guca1a+/COD3 and a 46% loss in Guca1aCOD3/COD3 mice. At 12 months of age (e), this has progressed to a 32% loss in Guca1a+/COD3 and a 49%
loss in Guca1aCOD3/COD3 mice. * indicates statistical significance at the 1% probability level. Note that in the lower panels of (a), PNA shows non-cone
staining above the ONL and INL. INL inner nuclear layer, ONL outer nuclear layer, IS/OS inner segment/outer segment.
doi:10.1371/journal.pone.0018089.g008
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0.1 mg/ml in PBS overnight at 4uC. Retinas were washed
extensively in PBS and dissected from the eyecup, radial cuts
were made to flatten the retina, and the retinas were mounted with
fluorescent aqueous mounting medium (Dako Ltd., Ely UK),
photoreceptor cell layer uppermost, using a coverslip.
Semi-thin sections
Prior to fixation, eyes for semithin sectioning were orientated
with a suture on the nasal aspect of the eyes. Eyes were immersion
fixed in 3% glutaraldehyde and 1% paraformaldehyde buffered to
pH 7.4 with 0.07 M sodium cacodylate-HCL. After a minimum of
12 h of fixation, the cornea and lens were removed. The posterior
segments were then osmicated for 2 h with a 1% aqueous solution
of osmium tetroxide and dehydrated through ascending alcohols
(50–100%, 10 min per step). After three changes of 100% ethanol,
the specimens were passed through propylene oxide (2620 min)
and left overnight in a 50:50 mixture of propylene oxide and
araldite. Following a single change to fresh araldite (5 h with
rotation), the specimens were embedded and cured for 24 h at
60uC. Using the nasal suture, the eyes were embedded sagittally so
that sectioning occurred in the vertical plane and the retinal
sections contained the superior and inferior retina. Semithin
(0.7 mm) sections were cut using a Leica Ultracut S microtome
fitted with an appropriate diamond knife (Diatome histoknife
Jumbo or Diatome Ultrathin). Semithin sections were stained with
1% toluidine blue and evaluated using a Leitz Diaplan microscope
fitted with a Leica digital camera DC 500 for image capture.
Paraffin histology and photoreceptor quantification
Following cervical dislocation, eyes were fixed for 24 h at 4uC
by incubation in ice-cold neutral buffered 10% (v/v) formalin; a
corneal puncture was created to allow the fixative to penetrate the
eye. Eyes (n = 6 eyes for each genotype) were processed in an
automated machine (Leica TP1020) then embedded in paraffin
blocks for sectioning. Sections were cut on a microtome at
6 microns, and mounted on polylysine coated slides (Thermofisher
Loughborough, UK). Sections were counterstained with haema-
toxylin (staining nuclei), and mounted using DPX (VWR,
Leicester UK). Light microscope images were taken of sections
at fixed positions in the eye in relation to the optic nerve head, and
the number of photoreceptor nuclei in the ONL was counted in
ten sections per eye.
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